# Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery

> **NCT01696955** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 81 (actual)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma
- Recurrent Head and Neck Carcinoma

## Interventions

- **BIOLOGICAL:** Cetuximab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Tivantinib

## Key facts

- **NCT ID:** NCT01696955
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-20
- **Primary completion:** 2017-05-05
- **Final completion:** 2017-05-05
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2018-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01696955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01696955, "Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01696955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*